Bkz
Bkz

BIMZELX: THE FIRST AND ONLY APPROVED DUAL SELECTIVE INHIBITOR OF IL-17A AND IL-17F FOR USE IN PSA AND AXSPA1–5

BLOCKING IL-17A AND IL-17F IN VITRO RESULTED IN SUPERIOR INHIBITION OF INFLAMMATORY RESPONSES VS BLOCKING IL-17A ALONE6

MOA new
MOA Box

MORE INFORMATION

Home teaser

HOMEPAGE

AXSPA Teaser

axSpA

PSA Teaser new

PsA

Abbreviations

axSpA, axial spondyloarthritis; IL, interleukin; IL-17 RA, interleukin 17 receptor A; IL-17 RC, interleukin receptor C; PsA, psoriatic arthritis.

References

  1. Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523–532..
  2. van Baarsen LGM, Lebre MC, van der Coelen D, et al. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res Ther. 2014;16(4):426.
  3. BIMZELX® EU SmPC. Psoriatic arthritis. https://www.ema.europa.eu/en. Accessed June 2023.
  4. BIMZELX® EU SmPC. Axial spondyloarthritis. https://www.ema.europa.eu/en. Accessed June 2023.
  5. McInnes IB, Asahina A, Coates LC, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet. 2023;401(10370):25–37.
  6. Merola JF, Landewé R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet. 2023;401(10370):38–48.
  7. van der Heijde D, Deodhar A, Baraliakos X, et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis. 2023. 82(4):515–526.

This content is intended for Healthcare Professionals only.

SE-P-BK-axSpA-2300028.
Date of preparation June 2023.

Har du någon fråga?

Välkommen att boka en tid med en UCB representant för att diskutera dina frågor mer i detalj.

Detta formulär skall ej användas för att rapportera någon biverkan eller produktreklamation. Om du önskar göra detta vänligen gör det via de sedvanliga kanalerna eller kontakta oss via formuläret här.